Related by context. All words. (Click for frequent words.) 69 EGFR tyrosine kinase inhibitors 69 dasatinib Sprycel 69 ENMD # 68 gefitinib Iressa 68 thalidomide Thalomid 68 receptor tyrosine kinase inhibitor 68 mTOR inhibitors 68 effector function 68 tyrosine kinase inhibitor TKI 68 CBLC# 68 gemcitabine Gemzar 68 endocrine therapies 68 erlotinib Tarceva 68 K ras mutations 67 tumorigenicity 67 XmAb# 67 predictive biomarkers 67 alvespimycin 67 Gleevec resistant 67 MGd 67 metaglidasen 67 erlotinib Tarceva ® 67 imatinib Gleevec 67 Symadex 67 Xanafide 67 SERMs 66 fulvestrant 66 APTIVUS r 66 EGFR inhibitors 66 galiximab 66 Gefitinib 66 immune modulating 66 Platinol ® cisplatin 66 trabectedin 66 JAK inhibitors 66 targeted antifolate 66 MEK inhibitors 66 acadesine 66 gefitinib 66 BRAF V#E mutation 66 liposomal formulation 66 EGFR TKI 66 imatinib therapy 66 pharmacodynamic PD 66 relapsed MM 66 HER2 overexpression 66 nilotinib Tasigna 66 vinca alkaloid 66 selective modulator 66 TKIs 65 proteasome inhibitor 65 alkylating agent 65 antiangiogenic agent 65 vorinostat 65 tyrosine kinase inhibitor 65 MAGE A3 ASCI 65 Clusterin 65 microtubule inhibitor 65 Panzem R NCD 65 ALK inhibitors 65 chemoresistance 65 Traficet EN 65 potent cytotoxic 65 eTag assays 65 VEGF inhibitors 65 HGS# 65 haematopoietic 65 sorafenib Nexavar 65 elotuzumab 65 AKT inhibitor 65 tumor subtypes 65 enzastaurin 65 histone deacetylase inhibitor 65 VAPRISOL 65 JAK inhibitor 65 antiangiogenic agents 65 CD# monoclonal antibody 65 mycophenolate mofetil 65 myelofibrosis polycythemia vera 65 Factor VIIa 65 cediranib 65 flavopiridol 65 somatostatin analogue 65 hypomethylating agents 65 xenograft models 65 antithrombotic 65 YONDELIS 65 metastatic neuroendocrine tumors 65 NS4A 65 Zevalin consolidation 65 polycythemia vera PV 65 Dasatinib 65 selective inhibition 65 T#I [002] 65 insulin sensitizing 65 antiangiogenic 64 bevacizumab Avastin ® 64 chemopreventive agent 64 diagnostic biomarker 64 talabostat 64 PKC# 64 cytoprotective 64 atacicept 64 HuMax CD4 64 humanized antibody 64 pharmacokinetic interactions 64 oral prodrug 64 GRASPA ® 64 metastatic RCC 64 menadione 64 PRT# 64 therapeutic regimens 64 anti CD3 64 lenalidomide dexamethasone 64 AEG# 64 Fludara ® 64 tumor necrosis 64 somatostatin analog 64 MMP inhibitors 64 gemcitabine Gemzar ® 64 bendamustine 64 PARP inhibition 64 cisplatin resistant 64 IAP inhibitor 64 HSP# inhibitor 64 small molecule activators 64 rituximab Rituxan 64 antiangiogenic therapy 64 trastuzumab Herceptin ® 64 evaluating tivozanib 64 Epidermal Growth Factor Receptor 64 BrachySil TM 64 epithelial tumors 64 CYT# potent vascular disrupting 64 OXi# 64 tyrosine kinase inhibitors 64 pertussis toxin 64 concurrent chemoradiation 64 TRAIL induced apoptosis 64 CCR5 antagonist 64 gastrointestinal stromal tumors GISTs 64 riociguat 64 liposomal doxorubicin 64 epothilone 64 relapsed ovarian cancer 64 kidney urologic 64 Leydig cells 64 miRview mets 64 volociximab 64 Amrubicin 64 biomarker identification 64 Adenoscan 64 CCX# 64 recurrent NSCLC 64 pegylated liposomal doxorubicin 64 alpha#beta# integrin 64 Amplimexon 64 molecularly targeted 64 DEB# 64 HIF PH inhibitors 64 dasatinib 64 denileukin diftitox 64 PDE4 inhibitor 64 idraparinux 64 MYDICAR ® 64 anticancer therapies 64 LHRH receptor positive 64 PI3K inhibitor 64 CB1 antagonists 64 PIK3CA 64 non nucleoside 64 elvucitabine 64 cilengitide 64 C. difficile toxins 64 CTAP# Capsules 64 Revlimid lenalidomide 63 TTR gene 63 cathepsin K inhibitor 63 Preclinical studies suggest 63 Lixivaptan 63 docetaxel Taxotere ® 63 DXL# 63 Fibroblast Growth Factor Receptor 63 SPRYCEL ® 63 amrubicin 63 erlotinib 63 anti CD3 antibody 63 bortezomib Velcade 63 K RAS 63 nilotinib 63 HQK 63 NMDA antagonists 63 histone deacetylase inhibitors 63 goserelin 63 Lenalidomide 63 abacavir lamivudine 63 paclitaxel Taxol 63 FLT3 63 Erlotinib 63 MAXY G# 63 Velcade bortezomib 63 kinase inhibition 63 pharmacodynamic biomarkers 63 TLR9 agonist 63 EGFR mutation status 63 antiproliferative effects 63 antiarrhythmic 63 idarubicin 63 PNP inhibitor 63 ritonavir boosted 63 bleomycin 63 chromosome #p# [002] 63 p# biomarker 63 posaconazole 63 genotypic resistance 63 Protein Kinase C 63 T#M mutation 63 imetelstat 63 gemtuzumab ozogamicin 63 NNRTIs 63 immunomodulation 63 cytotoxic chemotherapy 63 imatinib resistance 63 caspofungin 63 protease inhibitor PI 63 BMS # 63 PI3K AKT 63 antitumor effect 63 thiopurine 63 CANCIDAS 63 neoadjuvant chemotherapy 63 lenalidomide Revlimid R 63 fosbretabulin 63 CCR5 inhibitor 63 velafermin 63 efalizumab 63 nucleotide analog 63 Aplidin 63 anti angiogenic agents 63 Deforolimus 63 pharmacodynamic markers 63 NTDDS 63 c MYC 63 RRM1 63 pDCs 63 Octreolin 63 Pertuzumab 63 small molecule Hedgehog 63 apoptotic pathway 63 immunomodulatory therapy 63 pertuzumab 63 PI3K inhibitors 63 antitumoral 63 olmesartan 63 Blinatumomab 63 Temsirolimus 63 ziconotide 63 immune modulatory 63 sitaxsentan 63 direct thrombin inhibitors 63 fluoropyrimidine 63 OncoVEX 63 Neulasta ® 63 prostate carcinoma 63 MetMAb 63 taxane therapy 63 NPM1 63 weekly subcutaneous injections 63 BCR ABL mutations 63 uric acid lowering 63 myeloproliferative 62 GRNVAC1 62 recurrent glioblastoma multiforme 62 mutational status 62 bexarotene 62 molecular biomarkers 62 pan HDAC inhibitor 62 Annamycin 62 ADP receptor antagonist 62 IGF IR 62 KRAS mutant 62 vinorelbine tartrate 62 Telintra 62 Epigenomics proprietary 62 HMG CoA reductase inhibitors 62 cytostatic 62 nucleoside analog 62 canakinumab 62 Epratuzumab 62 viral kinetics 62 dexamethasone Decadron 62 nilotinib Tasigna ® 62 mGlu2 3 62 vapreotide acetate 62 mertansine 62 chemotherapeutic drug 62 #D#C# 62 EGFR HER2 62 visilizumab 62 sargramostim 62 anti CD# antibodies 62 vidofludimus 62 Bezielle 62 taxane chemotherapy 62 neratinib 62 OHR/AVR# 62 mRCC 62 depsipeptide 62 ELACYT 62 Bcr Abl mutations 62 somatostatin analogues 62 Aflibercept 62 interferon lambda 62 ganetespib 62 TNFa 62 Ceflatonin 62 EGFR inhibition 62 GV# [001] 62 chemosensitivity 62 Nexavar sorafenib 62 TKI therapy 62 intravesical 62 AQ4N 62 demethylating agent 62 interferon IFN 62 inactivating mutations 62 immunomodulatory effects 62 prostate cancer CaP 62 pleiotropic 62 cetuximab Erbitux R 62 PDE4 inhibitors 62 PEGPH# 62 FK# 62 hepatoma 62 ALK inhibitor 62 proteasome inhibitors 62 constitutively active 62 oral antiviral 62 DFMO 62 bazedoxifene conjugated estrogens 62 imatinib resistant 62 sulphonylureas 62 lapatinib Tykerb 62 multiple myeloma MM 62 Cx# [002] 62 novel VDA molecule 62 β blockers 62 promoter methylation 62 JAK2 inhibitor 62 gene rearrangements 62 histone deacetylases 62 renoprotective 62 alefacept 62 histone deacetylase HDAC 62 epigenetic therapies 62 peritoneal carcinomatosis 62 chemoresistant 62 IFN beta 62 retaspimycin 62 predictive biomarker 62 sipuleucel T 62 LHRH agonists 62 calcitriol 62 TG# [003] 62 Gleevec imatinib mesylate 62 Interferon beta 62 Anthracycline 62 pentamidine 62 cytolytic 62 micrometastasis 62 synthetic analogues 62 pancreatic adenocarcinoma 62 EGFR tyrosine kinase inhibitor 62 relapsed ALL 62 JAK2 inhibitors 62 Tasigna prolongs 62 tubulin inhibitor 62 receptor antagonists 62 decitabine 62 IRX 2 62 Thiovir 62 BAY #-# 62 etoposide 62 Tyrima 62 murine models 62 CIMZIA ™ 62 thymidylate synthase TS 62 prostate cancer PCa 62 anti fibrotic 62 corticosteroid dexamethasone 62 SNT MC# 62 syngeneic 62 IFN ß 62 ABCB1 62 teriflunomide 62 miconazole Lauriad ® 62 kinase inhibitors 62 Vimpat R 62 Vilazodone 62 Degarelix 62 glatiramer 62 gamma secretase inhibitor 62 anti amnesic 62 refractory prostate cancer 62 tipranavir ritonavir 62 Eraxis 62 A3 adenosine receptor 62 SSc 62 orally bioavailable 62 metastatic malignant 62 micafungin 62 myeloproliferative diseases 62 erythropoietic 62 VEGF receptor 62 CD# antibodies 62 dasatinib Sprycel ® 62 TOP2A 62 virotherapy 62 nelfinavir 62 ERBB2 62 oncolytic virus 62 tumorigenic 62 Aplidin R 62 paricalcitol 62 multitargeted 62 humanised monoclonal antibody 62 nucleoside analogues 62 iPSC 62 thienopyridine 62 activating mutations 62 Akt activation 62 null responder 62 DNA methyltransferases 62 IFN α 62 docetaxel Taxotere R 62 intravenous bisphosphonates 62 CYP #D# 61 monoclonal antibody MAb 61 NPM1 mutation 61 rufinamide 61 TNF α 61 PXD# 61 pharmacogenetic 61 Curaxin 61 gastrointestinal stromal tumor GIST 61 Onconase 61 TELINTRA 61 antiangiogenesis 61 OncoVEX GM CSF 61 Plicera 61 KRAS mutations 61 letrozole Femara 61 TIMP 1 61 presymptomatic 61 Dapagliflozin 61 p# inhibitor 61 antifibrotic 61 splice variants 61 cidofovir 61 Guanilib 61 fusion enhancers 61 Fludarabine 61 pharmacodynamics PD 61 Tesmilifene 61 generation purine nucleoside 61 Pegloticase 61 pegylated interferons 61 azacitidine 61 platelet inhibitor 61 trastuzumab Herceptin 61 protein kinase inhibitor 61 tipifarnib 61 PSMA ADC 61 anticancer therapy 61 fibrinolytic 61 antithrombotics 61 p# activation 61 TroVax ® 61 either acutely decompensated 61 regorafenib 61 peptide antigens 61 adipogenic 61 androgen receptor AR 61 sulindac 61 immunosuppressant drug 61 hypermethylated 61 STRIDE PD 61 Cloretazine 61 LRP5 61 Cytolin ® 61 GHRH 61 Vidaza ® 61 anti leukemic 61 Nilotinib 61 mapatumumab 61 vivo potency 61 bicalutamide 61 vemurafenib 61 Tarceva TM 61 oxaliplatin Eloxatin 61 imatinib Gleevec ® 61 CsA 61 plasma pharmacokinetics 61 CYC# 61 Tarceva erlotinib 61 QTc prolongation 61 romidepsin 61 Vaprisol 61 investigational humanized monoclonal antibody 61 antihormonal 61 HDAC inhibitors 61 EOquin 61 superficial bladder cancer 61 desvenlafaxine succinate 61 FUSILEV enhances 61 histamine dihydrochloride 61 LEUKINE 61 ISF# 61 radiation sensitizer 61 therapeutic monoclonal antibody 61 ReN# 61 florbetaben 61 VitiGam 61 imatinib 61 deacetylation 61 VKORC1 61 small molecule thrombopoietin 61 cMET 61 APTIVUS ritonavir 61 miglustat 61 independent prognostic marker 61 PDGF receptor 61 Azedra 61 CYP#A# substrate 61 DU #b 61 tigecycline 61 hypereosinophilic syndrome 61 REMINYL ® 61 5FU 61 Vidofludimus 61 IIIa inhibitor 61 adenoviral 61 mitochondrial toxicity 61 Combidex 61 farletuzumab 61 AV HALT 61 mutated K ras 61 intravenous cyclophosphamide 61 TLR9 agonists 61 Pazopanib 61 Cloretazine VNP#M 61 chlamydial 61 anthracycline containing 61 antiandrogen 61 CA9 SCAN 61 leukemia AML 61 CLORETAZINE TM VNP#M 61 Bortezomib 61 synthetic retinoid 61 Triapine 61 Trastuzumab 61 invasive candidiasis 61 lipid lowering therapies 61 thienopyridines 61 myeloproliferative disorders 61 liposomal amphotericin B 61 immunomodulator 61 NSCLC tumors 61 thalidomide dexamethasone 61 genotypic 61 CEQ# 61 receptor inhibitor 61 Pseudomonas aeruginosa infections 61 SCCHN 61 EGFR mutations 61 SGLT2 inhibitors 61 FVIIa 61 vascular disrupting agents 61 Denufosol 61 busulfan 61 TOCOSOL Camptothecin 61 Aurora kinase 61 reteplase 61 mutated KRAS 61 Genz # 61 AZT zidovudine Retrovir 61 Zolinza 61 Anticalins ® 61 NOD SCID mice 61 OncoVex 61 selective inhibitors 61 Hedgehog inhibitor 61 chemotherapy induced neutropenia 61 ZOLINZA 61 Altastaph 61 XYOTAX TM 61 nucleoside analogs 61 protein tyrosine phosphatase 61 BRAF mutation 61 BAL# [002] 61 demonstrated antitumor activity 61 GW# [003] 61 prognostic marker 61 eniluracil 61 retinoid 61 SUTENT ® 61 Aurora Kinase 61 myopathy rhabdomyolysis 61 peptide conjugated 61 HDACi 61 oral rivaroxaban 61 PROCHYMAL 61 thyroid carcinoma 61 capecitabine Xeloda 61 aspirin clopidogrel 61 obatoclax 61 boosted protease inhibitor 61 olaparib 61 Targretin 61 CD# antibody [001] 61 preclinically 61 acetonide FA 61 mTOR inhibitor 61 colon carcinoma 61 sorafenib Nexavar ® 61 pharmacological chaperone 61 Candesartan 61 forodesine 61 gemcitabine carboplatin 61 iodixanol 61 pimozide 61 ceftazidime 61 prognostic biomarker 61 bezafibrate 61 candidates Azedra TM 61 OvaRex MAb 61 gemcitabine cisplatin 61 protease inhibitors PIs 61 SCH # 61 IFN alpha 61 tumor histology 61 radioprotective 61 Virologic 61 verteporfin 61 CDK inhibitor 61 HCV replicon 61 PTPN# 61 KRAS mutation 61 edifoligide 61 insulin sensitizers 61 quinolone 61 heparanase 61 replicon 61 Navelbine ® 61 intracoronary 61 colorectal cancer liver metastases 61 mecamylamine 61 antidiabetic 61 oral anticoagulation 61 RAS RAF MEK 61 BEXXAR 61 S/GSK# 61 serum biomarker 61 Pharmacokinetics PK 61 Cardiotoxicity 61 chemoprevention trials 61 pharmacologic intervention 61 immunohistochemical 61 CIN2 + 61 EHT AGN 61 p# MAPK 60 paclitaxel Taxol ® 60 breast cancer subtypes 60 SAR# [004] 60 androgen deprivation 60 Multimeric 60 postoperative ileus POI 60 IMA# 60 samalizumab 60 HCV NS5B polymerase 60 adriamycin 60 abacavir Ziagen 60 adefovir dipivoxil 60 biologic therapeutics 60 Paliperidone ER 60 Luteinizing Hormone Releasing Hormone 60 Hodgkin lymphoma HL 60 HDAC inhibition 60 Tamibarotene 60 Kinoid 60 selective agonists 60 endothelin receptor antagonists 60 ribavirin RBV 60 novel peptide 60 stratifying patients 60 APTIVUS 60 noninfectious uveitis 60 aromatase inhibitors AIs 60 GRN#L 60 hydroxychloroquine 60 ACZ# 60 myeloablative 60 thromboembolic disease 60 selective orally bioavailable 60 immunofluorescence staining 60 bevacizumab Avastin R 60 CHOP chemotherapy 60 gastric carcinomas 60 panitumumab Vectibix 60 Seliciclib 60 azacytidine 60 Xelox 60 anticancer therapeutics 60 Tavocept 60 fibrinolytic therapy 60 Irinotecan 60 NATRECOR ® 60 Liposomal 60 Tarvacin 60 dosage regimens 60 Annexin V 60 antimetabolite 60 NXL# 60 melphalan prednisone 60 metabolomic profiles 60 anti CD# antibody 60 Voreloxin 60 adverse cytogenetics 60 dimeglumine 60 overlapping toxicities 60 antitumor 60 EGF receptor 60 tanespimycin 60 delta isoform 60 Natalizumab 60 HER2 positive metastatic breast 60 PC3 cells 60 Aptivus ® 60 aromatase inhibitor therapy 60 targeted radiotherapeutic 60 ixabepilone 60 zileuton 60 Omacetaxine 60 Dalbavancin 60 DaTscan 60 microsatellite instability 60 trastuzumab emtansine T DM1 60 metastatic renal cell carcinoma 60 Hsp# inhibition 60 tropism testing 60 darunavir 60 etanercept Enbrel 60 Anti VEGF 60 Inhaled AAT 60 candidate CRLX# 60 ketolide antibiotic 60 JVRS 60 pegfilgrastim 60 #beta HSD1 60 FUS1 60 antiplatelet medications 60 Fulvestrant 60 etravirine 60 thyroid hormone receptor 60 HGS ETR1 60 antiandrogens 60 TNF antagonist 60 neuroprotectant 60 Vidaza azacitidine 60 SNP rs# [002] 60 ATL# [001] 60 5 HT3 receptor 60 adjuvant radiotherapy 60 Peginterferon alfa 2b 60 microtubule targeting 60 gene loci 60 isoenzyme 60 isoproterenol 60 FGFR2 60 Reverset 60 herpetic keratitis 60 myelodysplastic myeloproliferative diseases 60 HBeAg negative 60 KRAS status 60 pretargeting 60 mTOR inhibition 60 sunitinib Sutent 60 neuroregenerative 60 interferon therapy 60 DNA hypermethylation 60 HER3 60 tamoxifen Nolvadex ® 60 methylenetetrahydrofolate reductase 60 FGFR1 60 darunavir r 60 T SPOT.TB 60 refractory chronic lymphocytic 60 PrevOnco 60 tranilast 60 Neupogen ® 60 KRAS mutation status 60 TREANDA 60 interferon alfa 60 Gag polymorphisms 60 PD LID 60 Enkephalin 60 anti androgen 60 Vectibix monotherapy 60 immunosuppressive therapies 60 Anticalin ® 60 gadobutrol 60 EGFr 60 Myocet 60 oncologic outcomes 60 tumor vascular disrupting 60 angiotensin converting enzyme inhibitor 60 maturation inhibitors 60 papillary renal cell carcinoma 60 investigational therapies 60 EDEMA3 trial 60 IL 1ß 60 beta interferons 60 GAMMAGARD 60 dacarbazine DTIC 60 trastuzumab Herceptin R 60 LY# [003] 60 3TC lamivudine Epivir 60 KIT mutations 60 xanthine oxidase inhibitor 60 Aliskiren 60 standard chemotherapy regimen 60 Herceptin trastuzumab 60 mGluR2 NAM 60 chemoradiotherapy 60 angiogenesis inhibitor 60 Genotypic 60 Teriflunomide 60 orally administered inhibitor 60 shRNA libraries 60 prostate carcinogenesis 60 sunitinib malate 60 CA4P 60 MVA BN R 60 zoledronate 60 Abacavir 60 INTELENCE 60 urothelial bladder cancer 60 metastatic malignant melanoma 60 EGFR receptor 60 Sanvar R 60 PROSTVAC VF 60 Gleevec imatinib 60 APTIMA HPV 60 Enzastaurin 60 Mitoxantrone 60 oncolytic 60 postoperative chemotherapy 60 benzimidazole 60 antiangiogenic drugs 60 antiepileptics 60 T#M 60 pain palliation 60 midkine 60 chromosomal rearrangement 60 plasma kallikrein inhibitor 60 FOLFOX6 chemotherapy regimen 60 Corus CAD 60 TriRima 60 immunomodulating 60 ER CHOP 60 small molecule tyrosine 60 Taxol ® 60 Gammagard Liquid 60 Evoltra ® 60 delafloxacin 60 protein tyrosine phosphatase 1B 60 interferon gamma 1b 60 intravesical infusion therapy 60 vasogenic edema 60 GRNCM1 60 Neuradiab 60 prasugrel Effient 60 novel anticancer 60 endoglin 60 huC# DM4 60 verapamil 60 antiplatelet therapies 60 antidiabetic drugs 60 DAPT 60 daptomycin 60 KETEK 60 pro angiogenic 60 AMN# [001] 60 hematopoietic malignancies 60 immunomodulatory properties 60 sunitinib 60 IAP inhibitors 60 calcineurin inhibitors 60 oxcarbazepine 60 Immunotherapeutic 60 Elvitegravir 60 Fingolimod 60 fosamprenavir 60 Fc receptor 60 Mg Usa 60 histone deacetylase HDAC inhibitor 60 estramustine 60 theranostic 60 docetaxel chemotherapy 60 Camptothecin 60 galectin 3 60 NanoCrystal Technology 60 ON #.Na 60 cytotoxic therapy 60 ISTODAX 60 hypervascular tumors 60 5 FU leucovorin 60 PEG SN# 60 Doxil ® 60 lumiliximab 60 chemotherapeutic agent 60 OvaRex R 60 Azacitidine 60 malignant ascites 60 pharmacogenetic testing 60 amifostine 60 huN# DM1 60 receptor subtypes 60 Cyclosporin 60 OMP #M# 60 intensive lipid lowering 60 standard chemotherapy regimens 60 bovine thrombin 60 trimethoprim sulfamethoxazole 60 germline mutations 60 BEXXAR Therapeutic Regimen 60 INTERCEPT platelets 60 Faslodex 60 aripiprazole Abilify 60 PEGylated Fab fragment 60 microRNA biomarkers 60 BCR ABL inhibitor 60 GIST tumors 60 EpCAM 60 TNFα 60 E#F# 60 V#F mutation 60 Pralatrexate 60 pyrimethamine 60 Trofex 60 Bucindolol 59 GnRH agonist 59 VEGF receptor inhibitor 59 ZD# [001] 59 ULORIC 59 anti TNF 59 intratumoral 59 IL#B 59 Wellstat 59 Tolvaptan 59 humanized monoclonal 59 R sorafenib tablets 59 targeting CD# 59 antisense oligonucleotides 59 TriGrid ™ 59 CCR5 inhibitors 59 activating mutation 59 relapsed multiple myeloma 59 adjuvant tamoxifen 59 TAFA# 59 AST ALT 59 GnRH antagonist 59 Bayer HealthCare Onyx Pharmaceuticals 59 bispecific antibody 59 differentiated thyroid 59 acyclovir Lauriad R 59 anti mitotic 59 alpha blocker 59 anticancer agent 59 siRNA therapeutic 59 enzyme inhibitor 59 haloperidol Haldol 59 Corgentin 59 antitumor effects 59 Gemzar gemcitabine 59 Known hypersensitivity 59 unresectable tumors 59 rFSH 59 breast carcinoma 59 K#R [002] 59 CYP#A# CYP#D# 59 pharmacokinetic PK study 59 AGILECT R 59 voriconazole 59 rxRNA 59 HepDirect prodrug 59 Dabigatran etexilate 59 BARACLUDE R 59 scintigraphic